TY - JOUR
T1 - Análisis farmacoeconómico del esquema corto de praziquantel en el tratamiento de la neurocisticercosis
AU - Medina-Santillán, Roberto
AU - Mateos-García, Eduardo
AU - Reyes-García, Gerardo
AU - Castañeda-Hernández, Gilberto
AU - Sotelo, Julio
PY - 2002
Y1 - 2002
N2 - The effectiveness of the treatment of neurocysticercosis with praziquantel has been assessed in several clinical trials in the last 20 years. Most studies employed a dose of 50 mg/kg/day, three times at day during 2 weeks. Recently, a novel and brief dosage scheme of praziquantel has been described. This scheme employs three doses of 25 mg/kg, and all are administered separately on the same day, with interval of 2 hours. This scheme has a direct impact on direct costs (cost of drugs), with a 90% reduction of the traditional scheme. In addition to a favorable impact on direct costs, the impact on indirect costs is important: With the short-scheme, hospitalization in unnecessary, and costs of hospital visits for patient and family is avoided, with subsequent improvement of emotional status and family environment.
AB - The effectiveness of the treatment of neurocysticercosis with praziquantel has been assessed in several clinical trials in the last 20 years. Most studies employed a dose of 50 mg/kg/day, three times at day during 2 weeks. Recently, a novel and brief dosage scheme of praziquantel has been described. This scheme employs three doses of 25 mg/kg, and all are administered separately on the same day, with interval of 2 hours. This scheme has a direct impact on direct costs (cost of drugs), with a 90% reduction of the traditional scheme. In addition to a favorable impact on direct costs, the impact on indirect costs is important: With the short-scheme, hospitalization in unnecessary, and costs of hospital visits for patient and family is avoided, with subsequent improvement of emotional status and family environment.
KW - Analysis
KW - Cost-benefit
KW - Efficacy
KW - Neurocysticercosis
KW - Pharmacoeconomics
KW - Praziquantel
UR - http://www.scopus.com/inward/record.url?scp=0036240325&partnerID=8YFLogxK
M3 - Artículo de revisión
C2 - 12001432
AN - SCOPUS:0036240325
SN - 0016-3813
VL - 138
SP - 203
EP - 207
JO - Gaceta Medica de Mexico
JF - Gaceta Medica de Mexico
IS - 2
ER -